Daina Graybosch
Stock Analyst at Leerink Partners
(0.86)
# 3,920
Out of 5,057 analysts
103
Total ratings
38.36%
Success rate
-10.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.82 | +9.89% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.70 | +185.10% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.80 | +288.89% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $18.26 | -34.28% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $92.93 | +28.05% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.70 | +17.65% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.70 | +325.53% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $87.42 | -55.39% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $53.95 | -16.59% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.46 | +2,913.99% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $0.99 | +907.76% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $19.79 | +92.02% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.28 | +86.92% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $103.88 | +115.63% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.88 | +1,495.74% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.93 | +1,732.49% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.65 | +445.45% | 4 | Feb 25, 2022 |
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.82
Upside: +9.89%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.70
Upside: +185.10%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.80
Upside: +288.89%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $18.26
Upside: -34.28%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $92.93
Upside: +28.05%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.70
Upside: +17.65%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.70
Upside: +325.53%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $87.42
Upside: -55.39%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $53.95
Upside: -16.59%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.46
Upside: +2,913.99%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $0.99
Upside: +907.76%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $19.79
Upside: +92.02%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.28
Upside: +86.92%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $103.88
Upside: +115.63%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.88
Upside: +1,495.74%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.93
Upside: +1,732.49%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.65
Upside: +445.45%